Hasil Pencarian - Eric Angevin

  • Menampilkan 1 - 5 hasil dari 5
Perbaiki Hasil
  1. 1
    MET Receptor Amplification Drives Resistance to Anti-EGFR Therapies

    MET Receptor Amplification Drives Resistance to Anti-EGFR Therapies oleh Patricia Martin Romano, Eduardo Castanon, Antoine Hollebecque, Ludovic Lacroix, Nathalie Auger, Eric Angevin, Lambros Tselikas, Sami Ammari, Jean-Charles Soria, Christophe Massard

    Diterbitkan 2019-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    Serum soluble CD26/DPP4 titer variation is a potential prognostic biomarker in cancer therapy with a humanized anti-CD26 antibody

    Serum soluble CD26/DPP4 titer variation is a potential prognostic biomarker in cancer therapy with a humanized anti-CD26 antibody oleh Yutaro Kaneko, Ryo Hatano, Naoto Hirota, Nicolas Isambert, Véronique Trillet-Lenoir, Benoit You, Jérôme Alexandre, Gérard Zalcman, Fanny Valleix, Thomas Podoll, Yoshimi Umezawa, Seiichi Takao, Satoshi Iwata, Osamu Hosono, Tetsuo Taguchi, Taketo Yamada, Nam H. Dang, Kei Ohnuma, Eric Angevin, Chikao Morimoto

    Diterbitkan 2021-03-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    284 Integrated molecular characterization of primary resistance mechanisms to immune checkpoint blockade in advanced non-small cell lung carcinoma (a-NSCLC)

    284 Integrated molecular characterization of primary resistance mechanisms to immune checkpoint blockade in advanced non-small cell lung carcinoma (a-NSCLC) oleh Etienne Rouleau, Jean-Yves Scoazec, Aurélien Marabelle, Benjamin Besse, David Planchard, Jack Pollard, Angelique Biancotto, Marielle Chiron, Nathalie Chaput-Gras, DIB Colette, Eladio Marquez, Joon Sang Lee, Shu Yan, Cecile Combeau, Félix Blanc-Durand, Mihaela Aldea, Ludovic Lacroix, Saloomeh Rafie, Eric Angevin

    Diterbitkan 2021-11-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors

    First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors oleh Toshihiko Doi, John A Thompson, Omid Hamid, Adi Diab, Siwen Hu-Lieskovan, Jeffrey Chou, Jeffrey S Wasser, Patrick A Ott, Jean-Philippe Spano, Willeke Ros, Alison Forgie, Wenjing Yang, Ferry A L M Eskens, Alberto A Chiappori, Eric Angevin, Naiyer A Rizvi, Cen Guo, Anthony B El-Khoueiry

    Diterbitkan 2022-10-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    A Phase 1b Study of Telisotuzumab Vedotin in Combination With Nivolumab in Patients With NSCLC

    A Phase 1b Study of Telisotuzumab Vedotin in Combination With Nivolumab in Patients With NSCLC oleh D. Ross Camidge, MD, PhD, Fabrice Barlesi, MD, PhD, Jonathan W. Goldman, MD, Daniel Morgensztern, MD, Rebecca Heist, MD, MPH, Everett Vokes, MD, Eric Angevin, MD, PhD, David S. Hong, MD, Igor I. Rybkin, MD, Minal Barve, MD, Todd M. Bauer, MD, Angelo Delmonte, MD, Martin Dunbar, DrPH, Monica Motwani, PhD, Apurvasena Parikh, PhD, Elysa Noon, PhD, Jun Wu, MD, Vincent Blot, PhD, Karen Kelly, MD

    Diterbitkan 2022-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: